This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | Next revisionBoth sides next revision | ||
home:patients:protocol_overview [06.21.2019] – [Introduction to the Marshall Protocol] sallieq | home:patients:protocol_overview [06.21.2019] – [Introduction to the Marshall Protocol] sallieq | ||
---|---|---|---|
Line 6: | Line 6: | ||
The Marshall Protocol, sometimes referred to as the MP, was developed by a team led by Trevor Marshall, PhD, as an antimicrobial treatment for chronic inflammatory diseases. Most diseases of unknown cause are chronic inflammatory diseases, and almost 100% of patients with these diseases have responded to the treatment. On this site and others, chronic inflammatory diseases are sometimes referred to as the Th1 diseases. | The Marshall Protocol, sometimes referred to as the MP, was developed by a team led by Trevor Marshall, PhD, as an antimicrobial treatment for chronic inflammatory diseases. Most diseases of unknown cause are chronic inflammatory diseases, and almost 100% of patients with these diseases have responded to the treatment. On this site and others, chronic inflammatory diseases are sometimes referred to as the Th1 diseases. | ||
+ | |||
+ | Treatment on the MP requires a [[home: | ||
At its essence, the MP involves five key elements, each of which is supported by the [[home: | At its essence, the MP involves five key elements, each of which is supported by the [[home: | ||
Line 22: | Line 24: | ||
The objective of the MP is to safely activate a [[home: | The objective of the MP is to safely activate a [[home: | ||
- | Treatment on the MP requires a [[home: | ||
The MP is to be administered only by a [[home: | The MP is to be administered only by a [[home: |